1. Zajaczkowska, R, Kocot-Kepska, M, Leppert, W, Wrzosek, A, Mika, J, Wordliczek, J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451.
Google Scholar | Crossref2. Madsen, ML, Due, H, Ejskjaer, N, Jensen, P, Madsen, J, Dybkaer, K. Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemother Pharmacol. 2019;84(3):471–485.
Google Scholar | Crossref | Medline3. Starobova, H, Vetter, I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.
Google Scholar | Crossref | Medline4. Krishnamoorthy, SK, Relias, V, Sebastian, S, Jayaraman, V, Saif, MW. Management of regorafenib-related toxicities: a review. Therap Adv Gastroenterol. 2015;8(5):285–297.
Google Scholar | SAGE Journals | ISI5. Grothey, A, Van Cutsem, E, Sobrero, A, et al. CORRECT Study Group . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
Google Scholar | Crossref | Medline | ISI6. Pelosof, LC, Gerber, DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838–854.
Google Scholar | Crossref | Medline | ISI7. Thiers, BH, Sahn, RE, Callen, JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin. 2009;59(2):73–98.
Google Scholar | Crossref | Medline8. Shibata, C, Kato, J, Toda, N, et al. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report. J Med Case Rep. 2019;13(1):168.
Google Scholar | Crossref | Medline